Entasis Therapeutics Holdings Inc's stock had its IPO on September 26, 2018, making it an older stock than only 4.39% of US equities in our set.
The ratio of debt to operating expenses for Entasis Therapeutics Holdings Inc is higher than it is for about only 5.61% of US stocks.
Entasis Therapeutics Holdings Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -75.63%, greater than the shareholder yield of merely 6.2% of stocks in our set.
If you're looking for stocks that are quantitatively similar to Entasis Therapeutics Holdings Inc, a group of peers worth examining would be CBIO, CDTX, LOGC, VCNX, and PULM.
ETTX's SEC filings can be seen here. And to visit Entasis Therapeutics Holdings Inc's official web site, go to www.entasistx.com.
Entasis Therapeutics Holdings Inc. (ETTX) Company Bio
Entasis Therapeutics Inc. discovers and develops antibacterials to fight diseases caused by multidrug-resistant bacteria. It offers ETX2514, a broad-spectrum and potent inhibitor of class A, C, and D beta-lactamases that has activity against Acinetobacter baumannii, a gram-negative bacterium that causes severe infections, which are associated with high mortality; ETX0914, a novel oral antibiotic for the treatment of uncomplicated gonorrhea; and a drug discovery platform that focuses on developing novel antibacterials targeting serious gram-negative infections, such as pneumonia, infections of the blood, urinary tract infections, and infections following surgery. Entasis Therapeutics Inc. has strategic development collaboration with Zai Lab Limited. The company was founded in 2015 and is based in Waltham, Massachusetts. Entasis Therapeutics Inc. operates as a subsidiary of AstraZeneca PLC.
Entasis Therapeutics (ETTX) will issue 9.3M units at $2.675/unit, in a private placement to Innoviva and another institutional investor, for gross proceeds of ~$25M.Each unit consists of one common share and a warrant to purchase one common share at an exercise price of $2.675.Certain investors may elect to receive pre-funded warrants to purchase...
The National Institutes of Health ((NIH)) has awarded Entasis Therapeutics Holdings' (ETTX), an initial contract of ~$3M, with the potential to increase up to $15.5M, to be used for developing novel molecules from its non-β-lactam inhibitor ((NBP)) platform with expanded antimicrobial spectrum. Funding from the contract will support research towards...
When searching for risk/reward plays, look no further than penny stocks. These names trading for under $5 per share are considered to be some of the most controversial on the Street, and divide market watchers into two factions: critics and fans.The former brings a valid argument to the table. Stocks don’t just end up trading at such low levels; typically, there’s a very real reason for their bargain price tags. This can be weak fundamentals or headwinds that are too strong to overcome.As for the latter, the potential for an investment worth only pocket change to appreciate even a seemingly insignificant amount, the result of which could be massive percentage gains, is too enticing to ignore. Not to mention the low share price means you can carve out a bigger stake for less money upfron...